

Bio-Link Licensing Portfolio Q1 2018

	Program	Indication	Modality	Mechanism of Action	Owner	Discovery	Lead Generation	Pre-Clinical	Phase I	Phase II
Therapeutics	KT009	Chronic back pain	Growth factor	Regeneration of IVD tissue	Kunovus Technologies					
	Xanamem™	Alzheimer's disease	SM	Lowers CNS cortisol	Actinogen Medical					
	Irofulven	Castration resistant prostate cancer / Hepatic cell carcinoma	SM & companion diagnostic	Cytotoxicity	Oncology Venture					
	LiPlaCis®	Metastatic breast cancer	Cisplatin liposome formulation	LiPlaCis® technology for targeted delivery	Oncology Venture					
	APO010	Multiple myeloma / Metastatic breast cancer	Peptide & Companion diagnostic	Immuno-oncology	Oncology Venture					
	CNC332	Oncology	SM	Mitochondrial complex II inhibitor	Cancure					
	CNC225	Immuno-oncology	SM	Galectin inhibitor	Cancure					
	CD5-2	Immuno-oncology	Oligo nucleotide	Selective vascular endothelial-cadherin modulator	Centenary Institute & Mirrx Therapeutics					
	Dynamain II inhibitor	Immuno-oncology	SM	Dynamain II GTPase inhibitor	University of Queensland, CMRI, & University of Newcastle					
	Dynamain I inhibitor	Refractory epilepsy	SM	Dynamain I GTPase inhibitor	Children's Medical Research Institute & University of Newcastle					
	Deflexifol	Colorectal carcinoma / Solid tumours	5-FU / leucovorin formulation	Co-formulation to allow simultaneous dosing	FivepHusion					
	Program	Technology			Owner	Prototype	Proof of Concept	Clinical Validation	Product Registration	
	EVestG™	Objective assessment of neurological diseases and optimisation of CNS drug trials			Neural Diagnostics					
	Program	Technology			Owner	Preclinical Proof of Concept		Clinical Proof of Concept		
	Blockmir Technology	Oligonucleotide blockmir technology platform for drug discovery			Mirxx Therapeutics					
Research Tools	Akimba	Murine model for diabetic retinopathy			Lions Eye Institute					

LEGEND: SM: Small molecule; CMRI: Children's Medical Research Institute.